Abstract
To evaluate the safety and efficacy of therapy with etanercept and methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and mild hepatitis C virus (HCV) infection.
| Original language | English |
|---|---|
| Pages (from-to) | 286-292 |
| Number of pages | 7 |
| Journal | THE JOURNAL OF RHEUMATOLOGY |
| Volume | 41 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2014 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Rheumatology
- Immunology
Keywords
- Adult
- Aged
- Alanine Transaminase
- Antirheumatic Agents
- Arthritis
- Aspartate Aminotransferases
- Combination
- DISEASE ACTIVITY SCORE
- Drug Therapy
- Female
- GISEA
- HEALTH ASSESSMENT QUESTIONNAIRE
- Hepacivirus
- Hepatitis C
- Humans
- Immunoglobulin G
- Liver Function Tests
- Male
- Methotrexate
- Middle Aged
- Prospective Studies
- Receptors
- Rheumatoid
- Severity of Illness Index
- TNF-α INHIBITORS
- TRANSAMINASES
- Treatment Outcome
- Tumor Necrosis Factor
- Viral Load
- Virus Replication
Fingerprint
Dive into the research topics of 'Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver